H.C. Wainwright Maintains Century Therapeutics(IPSC.US) With Buy Rating, Cuts Target Price to $9
H.C. Wainwright analyst Mitchell Kapoor maintains $Century Therapeutics(IPSC.US)$ with a buy rating, and adjusts the target price from $11 to $9.According to TipRanks data, the analyst has a success
Robinhood To Rally Around 29%? Here Are 10 Top Analyst Forecasts For Thursday
HC Wainwright & Co. Maintains Buy on Century Therapeutics, Lowers Price Target to $9
Century Therapeutics Analyst Ratings
Buy Rating for Century Therapeutics Amidst Shift in Cell Therapy Market and Safety Concerns of Competitors
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cronos Group (CRON), Relay Therapeutics (RLAY) and Century Therapeutics (IPSC)
Hold Rating on Century Therapeutics Amid Early-Stage Trials and Competitive Landscape
Century Therapeutics GAAP EPS of -$0.38, Revenue of $0.8M
Century Therapeutics | 10-Q: Q2 2024 Earnings Report
Century Therapeutics: Runway to Support Operations Into 2026 >IPSC
Century Therapeutics 2Q Loss $31.2M >IPSC
Century Therapeutics 2Q Loss/Shr 38c >IPSC
Earnings Flash (IPSC) CENTURY THERAPEUTICS Posts Q2 Revenue $771,000
Express News | Century Therapeutics Inc: Expects Full Year Gaap Opex to Be Between $150 Mln and $160 Mln.
Express News | Century Therapeutics Inc: Ended Q2 2024 With Cash, Cash Equivalents, and Investments of $269.6 Mln; Cash Runway Expected Into 2026
Express News | Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
Express News | Century Therapeutics Q2 Net Income USD -31.207 Million
Press Release: Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
Century Therapeutics, Inc.'s (NASDAQ:IPSC) Latest 25% Decline Adds to One-year Losses, Institutional Investors May Consider Drastic Measures
After Losing 17% in the Past Year, Century Therapeutics, Inc. (NASDAQ:IPSC) Institutional Owners Must Be Relieved by the Recent Gain